Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,254 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Structural modifications induced by specific HIV-1 protease-compensatory mutations have an impact on the virological response to a first-line lopinavir/ritonavir-containing regimen.
Alteri C, Artese A, Beheydt G, Santoro MM, Costa G, Parrotta L, Bertoli A, Gori C, Orchi N, Girardi E, Antinori A, Alcaro S, d'Arminio Monforte A, Theys K, Vandamme AM, Ceccherini-Silberstein F, Svicher V, Perno CF. Alteri C, et al. Among authors: costa g. J Antimicrob Chemother. 2013 Oct;68(10):2205-9. doi: 10.1093/jac/dkt173. Epub 2013 May 17. J Antimicrob Chemother. 2013. PMID: 23687186
Different evolution of genotypic resistance profiles to emtricitabine versus lamivudine in tenofovir-containing regimens.
Svicher V, Alteri C, Artese A, Forbici F, Santoro MM, Schols D, Van Laethem K, Alcaro S, Costa G, Tommasi C, Zaccarelli M, Narciso P, Antinori A, Ceccherini-Silberstein F, Balzarini J, Perno CF. Svicher V, et al. Among authors: costa g. J Acquir Immune Defic Syndr. 2010 Nov;55(3):336-44. doi: 10.1097/QAI.0b013e3181e6763f. J Acquir Immune Defic Syndr. 2010. PMID: 20739898
Specific HIV-1 integrase polymorphisms change their prevalence in untreated versus antiretroviral-treated HIV-1-infected patients, all naive to integrase inhibitors.
Ceccherini-Silberstein F, Malet I, Fabeni L, Dimonte S, Svicher V, D'Arrigo R, Artese A, Costa G, Bono S, Alcaro S, Monforte Ad, Katlama C, Calvez V, Antinori A, Marcelin AG, Perno CF. Ceccherini-Silberstein F, et al. Among authors: costa g. J Antimicrob Chemother. 2010 Nov;65(11):2305-18. doi: 10.1093/jac/dkq326. Epub 2010 Sep 3. J Antimicrob Chemother. 2010. PMID: 20817922
Docking analysis and resistance evaluation of clinically relevant mutations associated with the HIV-1 non-nucleoside reverse transcriptase inhibitors nevirapine, efavirenz and etravirine.
Alcaro S, Alteri C, Artese A, Ceccherini-Silberstein F, Costa G, Ortuso F, Bertoli A, Forbici F, Santoro MM, Parrotta L, Flandre P, Masquelier B, Descamps D, Calvez V, Marcelin AG, Perno CF, Sing T, Svicher V. Alcaro S, et al. Among authors: costa g. ChemMedChem. 2011 Dec 9;6(12):2203-13. doi: 10.1002/cmdc.201100362. Epub 2011 Sep 27. ChemMedChem. 2011. PMID: 21953939
Identification and structural characterization of novel genetic elements in the HIV-1 V3 loop regulating coreceptor usage.
Svicher V, Alteri C, Artese A, Zhang JM, Costa G, Mercurio F, D'Arrigo R, Alcaro S, Palù G, Clementi M, Zazzi M, Andreoni M, Antinori A, Lazzarin A, Ceccherini-Silberstein F, Perno CF; OSCAR study group. Svicher V, et al. Among authors: costa g. Antivir Ther. 2011;16(7):1035-45. doi: 10.3851/IMP1862. Antivir Ther. 2011. PMID: 22024519
HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors.
Cento V, Mirabelli C, Salpini R, Dimonte S, Artese A, Costa G, Mercurio F, Svicher V, Parrotta L, Bertoli A, Ciotti M, Di Paolo D, Sarrecchia C, Andreoni M, Alcaro S, Angelico M, Perno CF, Ceccherini-Silberstein F. Cento V, et al. Among authors: costa g. PLoS One. 2012;7(7):e39652. doi: 10.1371/journal.pone.0039652. Epub 2012 Jul 6. PLoS One. 2012. PMID: 22792183 Free PMC article.
3,254 results